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Abstract 
The study by Galan and colleagues in the SU.FOL.OM3 collaborative group has added further confusion to 
the omega-3 story, which in this case largely derives from confusion in the study design. Confusion about 
the likely mechanism of cardiovascular protection and hence expected outcomes; confusion in the 
subject selection; confusion about the timing of intervention; confusion about the active components of 
fish oil. 
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The study by Galan and colleagues in the SU.FOL.OM3 collaborative 
group has added further confusion to the omega-3 story, which in this case 
largely derives from confusion in the study design. Confusion about the 
likely mechanism of cardiovascular protection and hence expected outcomes; 
confusion in the subject selection; confusion about the timing of 
intervention; confusion about the active components of fish oil. 
First: epidemiology emphasises reduced cardiovascular mortality with 
fatty fish consumption, especially from sudden cardiac (arrhythmic) death 
and heart failure. (1-4) Intervention trials that demonstrate reduced 
mortality often do so without preventing new ischaemic events. (5-6) This 
study population, by including acute coronary syndrome (ACS) and stroke in 
addition to post-MI patients demonstrates the primary expectation of 
ischaemia prevention and as a result includes less than 50% of subjects 
with a clear arrhythmic substrate or heart failure predisposition. This 
resulted in inclusion of mainly vascular primary endpoints including: non- 
fatal myocardial infarction; ischaemic stroke; death from fatal myocardial 
infarction or stroke; and aortic dissection (ACS was a secondary 
endpoint). What is the experimental evidence to suggest that fish oil can 
modify these events at low intakes? In contrast, experimental evidence 
suggests that the cardioprotective effects of fish oil are due primarily 
to their influence on cardiac function, which is dependent on omega-3 
polyunsaturated fatty acid (PUFA) incorporation into myocardial cell 
membranes (7-8) producing intrinsic cardiac outcomes. (6,9) There can be 
little expectation that the unstable angina and especially stroke patients 
will have an arrhythmic episode or heart failure that might be prevented 
by low dose omega-3 PUFA. Similarly, although ACS may be prevented by 
regular fish intake, (10) and there is an experimental basis for altered 
myocardial response to ischaemia and reperfusion by nutritional 
preconditioning, (11-12) (not reduced incidence of ischaemia), the 
likelihood of identifying a change in ACS is diluted by the >70% stroke 
and post-MI patients in the study population. 
Secondly: as noted by the authors, the mean interval between MI and 
entry into the study was 101 days. In the GISSI-P study subjects were 
recruited immediately post-MI (mean 16 days) and fatal arrhythmia 
prevention occurred early, with a significant difference in arrhythmic 
death evident by 120 days (close to the mean time of initial recruitment 
for subjects in this study). (6,13) 
Thirdly: the fish oil preparation contained omega-3 PUFA 
predominantly as the fatty acid EPA. Considering the importance of omega- 
3 PUFA incorporation into membranes to modify heart function and ischaemic 
vulnerability, the principal omega-3 PUFA in the heart is undoubtedly 
DHA,(14,15) and animal studies show that, when provided in the diet in low 
doses, pure DHA is antiarrhythmic but pure EPA is not. (16) Similarly, 
preferential effects of DHA have been reported in several human conditions 
modified by fish oils. Although the omega-3 PUFA product used in the 
GISSI studies had EPA>DHA, it provided 380 mg DHA daily, almost double 
the dose used in this study. (6,9) 
Fourthly: and not specific to this study, is the common 
consideration of EPA and DHA as equivalent and interchangeable. It is 
notable that the majority of food fish provide DHA in excess of EPA. (15) 
This may be an important contributor to the negative outcomes of this and 
other low-dose intervention studies which use high EPA oils (17) and which 
may not provide sufficient DHA to reproduce the effects associated with 
dietary habits in epidemiology.  
Intervention trials such as this will likely continue to fail to 
reproduce the promise of the epidemiology and experimental studies and 
fail to translate them into clinical practice while they fail to reproduce 
the conditions revealed by those studies. By consistently looking for 
outcomes that are not supported by experimental evidence and biological 
plausibility or predicted by epidemiology, and in failing to reproduce the 
fatty acid intakes typical of dietary intake from fish, they are setting 
themselves up to fail. Before the concept of fish oil intervention for 
cardioprotection is rejected, it is important that some low-dose 
intervention trials are instigated that use a DHA intake more consistent 
with regular consumption of fish and address evidence-based biologically 
plausible mechanisms using appropriate subject groups in each case.  
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